Effect of Myrrh in treatment of leishmaniasis

Phase 2

• Conditions: Cutaneous leishmaniasis.; Cutaneous leishmaniasis; B55.1

• Registration Number: IRCT20230903059337N1
• Lead Sponsor: Kerman University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Cutaneous leishmaniasis by leishmania major
Number of skin lesions less than 5
Ulcer size less than 5 cm
Duration of lesions no more than 3 months
Receiving no anti-leishmania treatment remedies during the past 3 months
Completing the informed consent form

Exclusion Criteria

Pregnancy and lactation
Underlying diseases and allergy
Lesions on joints, face and sensitive organs
Regional adenopathy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Size of Leishmania lesion. Timepoint: in 0,1,2,3,4,6,8 weeks of treatment. Method of measurement: WoundDesk app.;Induration of lesion. Timepoint: in 0,1,2,3,4,6,8 weeks of treatment. Method of measurement: Digital Caliper.;Wound healing time. Timepoint: in 0,1,2,3,4,6,8 weeks of treatment. Method of measurement: Counting of weeks.